531739 Stock Overview
Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products.
Gennex Laboratories Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₹6.60|
|52 Week High||₹12.90|
|52 Week Low||₹6.03|
|1 Month Change||-2.08%|
|3 Month Change||-21.80%|
|1 Year Change||-44.54%|
|3 Year Change||98.20%|
|5 Year Change||37.21%|
|Change since IPO||450.00%|
Recent News & Updates
|531739||IN Pharmaceuticals||IN Market|
Return vs Industry: 531739 underperformed the Indian Pharmaceuticals industry which returned -16.7% over the past year.
Return vs Market: 531739 underperformed the Indian Market which returned -0.1% over the past year.
|531739 Average Weekly Movement||8.1%|
|Pharmaceuticals Industry Average Movement||6.2%|
|Market Average Movement||6.8%|
|10% most volatile stocks in IN Market||9.7%|
|10% least volatile stocks in IN Market||4.4%|
Stable Share Price: 531739 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 531739's weekly volatility (8%) has been stable over the past year.
About the Company
Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers active pharmaceutical ingredients, including Guaifenesin, Methocarbamol, Fluconazole, Mephenesin, Phenazopyridine Hcl, Melitracen Hcl, Allopurinol, Ketoconazole, Domperidone, Flupentixol Di-Hydrochloride, Chlorphenesin, and Mefanemic Acid. It operates in India, Algeria, Argentina, Bangladesh, Bolivia, Colombia, Ecuador, Egypt, El Salvador, Germany, Guatemala, Iran, Israel, Jordan, Mexico, Nicaragua, Panama City, Peru, Saudi Arabia, Spain, Vietnam, and Yemen.
Gennex Laboratories Fundamentals Summary
|531739 fundamental statistics|
Is 531739 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|531739 income statement (TTM)|
|Cost of Revenue||₹381.03m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||0.31|
|Net Profit Margin||6.27%|
How did 531739 perform over the long term?See historical performance and comparison
Is 531739 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 531739?
Other financial metrics that can be useful for relative valuation.
|What is 531739's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 531739's PE Ratio compare to its peers?
|531739 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
VAISHALI Vaishali Pharma
524202 Lactose (India)
524506 Coral Laboratories
530163 Kerala Ayurveda
531739 Gennex Laboratories
Price-To-Earnings vs Peers: 531739 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the peer average (24.6x).
Price to Earnings Ratio vs Industry
How does 531739's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 531739 is good value based on its Price-To-Earnings Ratio (21.3x) compared to the Indian Pharmaceuticals industry average (21.5x)
Price to Earnings Ratio vs Fair Ratio
What is 531739's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||21.3x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 531739's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 531739 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 531739 (₹6.6) is trading below our estimate of fair value (₹72.76)
Significantly Below Fair Value: 531739 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 531739's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Gennex Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Gennex Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Gennex Laboratories is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Gennex Laboratories competitive advantages and company strategy can generally be found in its financial reports archived here.
How has Gennex Laboratories performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 531739 has high quality earnings.
Growing Profit Margin: 531739's current net profit margins (6.3%) are lower than last year (6.7%).
Past Earnings Growth Analysis
Earnings Trend: 531739's earnings have grown significantly by 24.2% per year over the past 5 years.
Accelerating Growth: 531739's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 531739 had negative earnings growth (-2.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9%).
Return on Equity
High ROE: 531739's Return on Equity (9%) is considered low.
Discover strong past performing companies
How is Gennex Laboratories's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 531739's short term assets (₹471.8M) exceed its short term liabilities (₹242.1M).
Long Term Liabilities: 531739's short term assets (₹471.8M) exceed its long term liabilities (₹31.0K).
Debt to Equity History and Analysis
Debt Level: 531739's net debt to equity ratio (4.1%) is considered satisfactory.
Reducing Debt: 531739's debt to equity ratio has increased from 12.9% to 23.1% over the past 5 years.
Debt Coverage: 531739's debt is well covered by operating cash flow (65.6%).
Interest Coverage: 531739's interest payments on its debt are well covered by EBIT (6.8x coverage).
Discover healthy companies
What is Gennex Laboratories's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 531739's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 531739's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 531739's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 531739's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 531739 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Arihant Baid (36 yo)
Mr. Arihant Baid has been Managing Director of Gennex Laboratories Limited since March 2011 and serves as its Executive Director since May 18, 2012. Mr. Baid serves as Chairman of Gennex Laboratories Limit...
CEO Compensation Analysis
Compensation vs Market: Arihant's total compensation ($USD38.21K) is about average for companies of similar size in the Indian market ($USD38.01K).
Compensation vs Earnings: Arihant's compensation has been consistent with company performance over the past year.
Experienced Management: 531739's management team is seasoned and experienced (7.4 years average tenure).
Experienced Board: 531739's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Gennex Laboratories Limited's employee growth, exchange listings and data sources
- Name: Gennex Laboratories Limited
- Ticker: 531739
- Exchange: BSE
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹834.920m
- Shares outstanding: 126.50m
- Website: https://www.gennexlab.com
Number of Employees
- Gennex Laboratories Limited
- Plot No. 144, Akash Ganga
- 3rd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/06 00:00|
|End of Day Share Price||2022/07/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.